HealthCare Global Enterprises: Strong Q1 FY27 Performance Driven by Oncology Focus

Consolidated revenue for HealthCare Global Enterprises reached ₹695.1 crore, a 13% increase year-on-year. Adjusted profit after tax (PAT) saw a significant jump of 190% to ₹13.8 crore.

Reader Takeaway: Volume growth fuels topline; new hospital ramp-up is a key watch point.

What just happened

HealthCare Global Enterprises (HCG) announced its financial results for the first quarter of FY27 (ending June 30, 2026). The company reported consolidated revenue of ₹695.1 crore, a 13% increase compared to the same period last year. Adjusted EBITDA grew by 20% to ₹133.9 crore, leading to an improved EBITDA margin of 19.4%. Adjusted PAT surged by 190% to ₹13.8 crore.

Why this matters

These results highlight HCG's focused strategy on its core oncology business. The growth is driven by an 11% increase in patient volumes, indicating strong demand for its services. The significant jump in profitability, outpacing revenue growth, signals improving operational efficiencies and effective cost management. The company's strategic divestment of its fertility business allows it to concentrate resources on expanding its oncology network.

The backstory

HealthCare Global Enterprises is a leading provider of cancer care services. The company has been expanding its network of hospitals and treatment centers, with a particular focus on complex oncology treatments. This quarter's performance builds on previous efforts to strengthen its market position and operational capabilities.

What changes now

The company's operational expansion continues with the commencement of a new 120-bed hospital in North Bangalore, which contributed ₹6.7 crore to revenue in its first quarter. HCG also added 121 operational beds across various locations and upgraded its Rajkot facility to a Comprehensive Cancer Care (CCC) center. The integration of new surgical robotic systems further enhances its treatment capabilities.

Risks to watch

A key watch point is the gestation loss incurred by the new North Bangalore facility, which reported a loss of ₹7.0 crore in Q1 FY27. Investors will be tracking the ramp-up and timeline for this facility to achieve breakeven and profitability. While overall margins are improving, the initial costs of new capacity need to be managed effectively.

Peer comparison

While specific peer comparisons for Q1 FY27 oncology-focused results are not detailed in the filing, HCG's broad-based revenue growth across 16 out of 25 centers suggests healthy market penetration. The focus on high-value oncology services positions it within a specialized segment of the healthcare industry.

Context metrics (time-bound)

• Consolidated Revenue (Q1 FY27): ₹695.1 crore (up 13% YoY)
• Adjusted EBITDA (Q1 FY27): ₹133.9 crore (up 20% YoY)
• Adjusted PAT (Q1 FY27): ₹13.8 crore (up 190% YoY)
• Volume Growth (YoY): 11%
• North Bangalore Facility Revenue (Q1 FY27): ₹6.7 crore
• North Bangalore Facility Loss (Q1 FY27): ₹7.0 crore

What to track next

Investors will be keen to monitor the operational performance and breakeven trajectory of the new North Bangalore hospital. The company's ability to sustain volume-led growth and further improve EBITDA margins across its network will be crucial. Continued expansion and upgrade of facilities, including the integration of advanced technologies, will also be key indicators of future performance.